Wei Su
Impact in
- Nephrology top 2%
- Chronic Kidney Disease and Diabetes
- Renal Diseases and Glomerulopathies
- Dialysis and Renal Disease Management
Papers in
-
- Ferroptosis and cancer prognosis 4
- Pulmonary Hypertension Research and Treatments 3
-
- Metabolomics and Mass Spectrometry Studies 2
- Co-authors
- Ying‐Yong Zhao (10 shared papers)Dan‐Qian Chen (6 shared papers)Nosratola D. Vaziri (6 shared papers)Hua Chen (5 shared papers)Xiao-Yong Yu (5 shared papers)Hua Miao (5 shared papers)Yan Guo (5 shared papers)Yanni Wang (4 shared papers)
- Journals
- Clinica Chimica Acta (2 papers)Cell Proliferation (2 papers)Frontiers in Immunology (2 papers)Acta Pharmacologica Sinica (2 papers)British Journal of Pharmacology (2 papers)
- Partner nations
- ChinaUnited StatesTaiwan
In The Last Decade
Wei Su
59 papers receiving 1.3k citations
Wei Su's Hit Papers
Peers
Comparison fields: 5 of 111
- Nephrology 241
- Biological Psychiatry 27
- Pharmacology 75
- Health, Toxicology and Mutagenesis 103
- Clinical Biochemistry 45
Countries citing papers authored by Wei Su
This map shows the geographic impact of Wei Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Su more than expected).
Fields of papers citing papers by Wei Su
This network shows the impact of papers produced by Wei Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Su. The network helps show where Wei Su may publish in the future.
Co-authors
The 25 scholars most cited alongside Wei Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 65 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 145 | |
| 2 | 2017 | 106 | |
| 3 | Lactobacillus species ameliorate membranous nephropathy through inhibiting the aryl hydrocarbon receptor pathway via tryptophan‐produced indole metabolites Hit paper breakdown → | 2023 | 93 |
| 4 | Targeting Lactobacillus johnsonii to reverse chronic kidney disease Hit paper breakdown → | 2024 | 76 |
| 5 | 2020 | 67 | |
| 6 | 2002 | 63 | |
| 7 | 2019 | 51 | |
| 8 | 2019 | 47 | |
| 9 | 2018 | 45 | |
| 10 | 2007 | 41 | |
| 11 | 2023 | 39 | |
| 12 | 2023 | 36 | |
| 13 | 2023 | 33 | |
| 14 | 2020 | 33 | |
| 15 | 2017 | 33 | |
| 16 | 2005 | 30 | |
| 17 | 2004 | 30 | |
| 18 | 2020 | 26 | |
| 19 | 2016 | 25 | |
| 20 | 2018 | 24 |
About Wei Su
Wei Su is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Nephrology, Oncology and Epidemiology, having authored 65 papers that have together received 1.4k indexed citations. Recurring topics across this work include Chronic Kidney Disease and Diabetes (5 papers), Ferroptosis and cancer prognosis (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), Pulmonary Hypertension Research and Treatments (3 papers), Renal Diseases and Glomerulopathies (3 papers), Reproductive Biology and Fertility (3 papers), Metabolomics and Mass Spectrometry Studies (2 papers) and Air Quality and Health Impacts (2 papers). The work is most often cited by research in Nephrology (241 citations), Biological Psychiatry (27 citations), Pharmacology (75 citations), Health, Toxicology and Mutagenesis (103 citations) and Clinical Biochemistry (45 citations). Wei Su has collaborated with scholars based in China, United States and Taiwan. Frequent co-authors include Ying‐Yong Zhao, Dan‐Qian Chen, Nosratola D. Vaziri, Hua Chen, Xiao-Yong Yu, Hua Miao, Yan Guo, Yanni Wang, Gang Cao and Xu Bai. Their work appears in journals such as Clinica Chimica Acta, Cell Proliferation, Frontiers in Immunology, Acta Pharmacologica Sinica and British Journal of Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.